
Last Price
52 Week Range
¥1.49K - ¥7.79B
Next Earnings Date
-
Next Earnings Date
-
Last Price
Market Cap | - |
EV | - |
Shares Outstanding | - |
Beta | - |
Industry | Household & Personal Products |
Analyst Rating | NO_OPINION |
Analyst Target Price | - |
Number of Analysts | 0 |
P/E 2025E | 18.66x |
P/Revenue 2025E | 0.77x |
Revenue | |
EPS | |
Operating Cash Flow | |
Free Cash Flow |
Revenue | |
EPS | |
Operating Cash Flow | |
Free Cash Flow |
Gross Margin 2025E | 33.70% |
Net Profit Margin 2025E | 4.11% |
ROE 2025E | 13.80% |
ROCE 2024 | 27.15% |
DPS 2025E | ¥0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR |
Price
%
1M
3M
6M
1Y
3Y
5Y

C.I. Medical Co.,Ltd.
3540
Sector
Consumer Defensive
Industry
Household & Personal Products
CEO
Shimizu, Kiyoto
Employees
Website
ci-medical.co.jpIPO Date
2016-06-17
Headquarters
Ni-152, Fukushima-town, Nomi, Ishikawa, 929-0112, Japan
The last closing price of C.I. Medical (3540) is ¥1493.00, reflecting a +0.07% change from the prior session. Last updated: January 1, 2026 at 1:34 AM Eastern Time
Review the recent 3540 stock performance trends:Past 1 Month: C.I. Medical (3540) shares have +0.07%.Past 3 Months: The stock has -0.33%.Past 6 Months: 3540 shares have +46.37%. Last updated: January 1, 2026 at 12:15 AM Eastern Time
Over the last year, C.I. Medical (3540) has established a 52-week price range between a high of ¥7784999900.00 and a low of ¥1492.00. This metric is essential for assessing the stock's annual volatility. Last updated: January 1, 2026 at 12:15 AM Eastern Time
A ¥1,000 investment in C.I. Medical 5 years ago, when the stock was trading around ¥1254.03, would be worth approximately ¥1190.56 today, based solely on share price performance (excluding dividends). This represents a total return of 19.06% over the period, equivalent to a compound annual growth rate (CAGR) of 3.55%. Past performance reflects historical price movements only and does not imply future results. Last updated: January 1, 2026 at 12:15 AM Eastern Time
In the most recently reported quarter, C.I. Medical (3540) generated ¥22.99B in revenue, representing a +9.82% year over year change. For the next quarter, analyst consensus currently expects revenue of approximately ¥26.64B, implying an expected +19.76% year over year change. Quarterly revenue results and expectations reflect underlying demand trends, pricing dynamics, product or service mix, seasonality, and broader macroeconomic conditions. Actual results may differ from consensus estimates as new information becomes available. Last updated: December 17, 2025 at 3:05 AM Eastern Time
In the most recently reported fiscal year, C.I. Medical (3540) generated net income of ¥6.27B, compared with ¥2.08B in the prior fiscal year, representing a +200.96% year over year change. For the upcoming fiscal year, analyst consensus currently estimates net income of ¥4.00B. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions. Last updated: December 17, 2025 at 3:05 AM Eastern Time
According to its latest quarterly filing, C.I. Medical (3540) reported EBITDA of ¥1.78B, representing a +367.81% year over year change. EBITDA is a non-GAAP measure and does not account for depreciation, amortization, interest expense, taxes, or capital expenditures. As a result, it should be considered alongside other financial metrics when assessing operating performance. Actual results may differ from estimates as company-specific or macroeconomic conditions evolve. Last updated: December 17, 2025 at 3:05 AM Eastern Time
Based on the latest available data, C.I. Medical (3540) is currently trading at a last twelve months (LTM) P/E ratio of 18.04x. The P/E ratio reflects how much investors are willing to pay today for a dollar of earnings and can vary meaningfully over time due to changes in profitability, growth expectations, margin outlook, and earnings volatility. Last updated: January 1, 2026 at 1:34 AM Eastern Time
In the most recently reported quarter, C.I. Medical (3540) revenue was ¥22.99B, compared with analyst consensus expectations of ¥24.60B, representing a -6.55% revenue surprise versus expectations. Earnings per share (EPS) for the quarter were ¥14.84. Revenue and EPS surprises may be positive or negative and can influence near-term stock performance depending on expectations, forward guidance, and broader market and sector conditions. For a detailed history of analyst expectations versus reported results, view the full estimates vs. actuals track record here: 👉 Estimates vs. Actuals Last updated: December 17, 2025 at 3:05 AM Eastern Time
Based on the latest available analyst coverage, C.I. Medical (3540) currently carries a NO_OPINION consensus rating. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: January 1, 2026 at 1:34 AM Eastern Time
Like other publicly traded stocks, C.I. Medical (3540) shares are bought and sold on stock exchanges such as TSE and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for C.I. Medical (3540) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.
At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add 3540 to your watchlist.
C.I. Medical trades under the ticker symbol 3540 on the TSE stock exchange. The ticker 3540 is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersNEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersGainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.